摘要
目的探讨糖尿病肾病患者应用前列地尔联合贝那普利治疗对其蛋白尿所产生的影响。方法择取我院2014年1月至2016年1月接受的300例糖尿病肾病患者作为研究对象,按数字奇偶法将其分为两组,每组150例。对照组应用贝那普利进行治疗,研究组患者应用贝那普利联合前列地尔治疗。观察比较两组患者的临床疗效及治疗前、后24 h尿蛋白含量及尿微白蛋白排泄率。结果研究组患者的治疗总有效率显著高于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者的尿蛋白含量及尿微白蛋白排泄率均降低,且研究组低于对照组(P<0.05)。结论糖尿病肾病患者应用贝那普利联合前列地尔治疗临床疗效显著,可明显降低其尿微白蛋白排泄率及尿蛋白含量,值得临床应用推广。
Objective To investigate the effect of alprostadil combined with benazepril in the treatment of proteinuria inpatients with diabetic nephropathy. Methods From January 2014 to January 2016, 300 patients with diabetic nephropathywere enrolled in this study. The patients were divided into two groups according to the digital parity method, with 150 casesin each group. The control group was treated with benazepril, and the study group was treated with benazepril and alprostadil.The clinical efficacy, urine protein content at 24 h before and after treatment, and the urinary microalbumin excretion rates ofthe two groups were compared. Results The total effective rate of the study group was significantly higher than that of thecontrol group（P〈0.05）; after treatment, the proteinuria content and urinary microalbumin excretion rates decreased in the twogroups, and those of the study group were lower than the control group（P〈0.05）. Conclusion Benazepril combined withalprostadil has remarkable effect in patients with diabetic nephropathy, it can significantly reduce urinary microalbuminexcretion rate and urinary protein content, which is worthy of clinical application and promotion.
作者
袁江红
贾全瑞
YUAN Jiang-hong;JIA Quan-rui(the People＇s Hospital of Tongchuan,Tongchuan 727000;Xi＇an Fengcheng Hospital,Xi＇an 710000,China)
出处
《临床医学研究与实践》
2018年第18期35-36,共2页
Clinical Research and Practice
